News

Charity cycle ride raises awareness and $1200 for Canterbury Urology Research Trust

Posted by on 13 Nov 2013 in News | Comments Off on Charity cycle ride raises awareness and $1200 for Canterbury Urology Research Trust

Charity cycle ride raises awareness and $1200 for Canterbury Urology Research Trust

With the support of his co-riders, 83 year old George Crack, a prostate cancer patient, cycled from Rolleston to Hinds. The total amount of money ($1200) raised from the Charity Cycle ride was donated to Canterbury Urology Research Trust. George is no stranger to long distance cycling. The 1965 Raleigh three speed he rode has been his transport through the length of New Zealand. In 1971 George was the first official cyclist to ride over the Auckland Harbour Bridge. With the Oamaru Penny Farthing and Vintage Cycle Club he has also ridden on...

read more

Help on the way for overactive bladders

Posted by on 20 Jun 2012 in News | 0 comments

Help on the way for overactive bladders

As well as taking part in many prostate cancer studies, Canterbury Urology Research Trust have a long history of experience in trials for people with Overactive Bladder (OAB). OAB is a urological condition defined by a set of symptoms: urgency, frequency, with or without urge incontinence. (Urge incontinence is the involuntary loss of urine due to bladder spasms or contractions.) It can be a common and distressing problem, which may have a profound impact on quality of life. It is estimated that OAB is prevalent in approximately 16% to 17% of...

read more

New Prostate Cancer treatment for New Zealand

Posted by on 19 Feb 2012 in News | 0 comments

New Prostate Cancer treatment for New Zealand

Thanks to the results of one of the prostate cancer trials Canterbury Urology Research Trust have been involved in, the U.S. Food and Drug Administration (FDA) has approved a new drug, Denosumab for use in prevention of skeletal-related events in patients with bone metastases. This makes Denosumab the first RANKL inhibitor to be approved by the FDA, and is now available for use in New Zealand.

read more